145 related articles for article (PubMed ID: 18077209)
1. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit.
Lipsic E; Westenbrink BD; van der Meer P; van der Harst P; Voors AA; van Veldhuisen DJ; Schoemaker RG; van Gilst WH
Eur J Heart Fail; 2008 Jan; 10(1):22-9. PubMed ID: 18077209
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction.
van der Meer P; Lipsic E; Henning RH; Boddeus K; van der Velden J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
J Am Coll Cardiol; 2005 Jul; 46(1):125-33. PubMed ID: 15992646
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization.
Westenbrink BD; Lipsic E; van der Meer P; van der Harst P; Oeseburg H; Du Marchie Sarvaas GJ; Koster J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
Eur Heart J; 2007 Aug; 28(16):2018-27. PubMed ID: 17576662
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure.
Westenbrink BD; Ruifrok WP; Voors AA; Tilton RG; van Veldhuisen DJ; Schoemaker RG; van Gilst WH; de Boer RA
Cardiovasc Res; 2010 Jul; 87(1):30-9. PubMed ID: 20139114
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia.
Westenbrink BD; Oeseburg H; Kleijn L; van der Harst P; Belonje AM; Voors AA; Schoemaker RG; de Boer RA; van Veldhuisen DJ; van Gilst WH
Cardiovasc Drugs Ther; 2008 Aug; 22(4):265-74. PubMed ID: 18327705
[TBL] [Abstract][Full Text] [Related]
6. Single high-dose intramyocardial administration of erythropoietin promotes early intracardiac proliferation, proves safety and restores cardiac performance after myocardial infarction in rats.
Gäbel R; Klopsch C; Furlani D; Yerebakan C; Li W; Ugurlucan M; Ma N; Steinhoff G
Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):20-5; discussion 25. PubMed ID: 19380336
[TBL] [Abstract][Full Text] [Related]
7. Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.
Tao ZW; Huang YW; Xia Q; Xu QW
Chin Med J (Engl); 2005 Jan; 118(2):146-54. PubMed ID: 15667801
[TBL] [Abstract][Full Text] [Related]
8. Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure.
Henderson KK; Danzi S; Paul JT; Leya G; Klein I; Samarel AM
Circ Heart Fail; 2009 May; 2(3):243-52. PubMed ID: 19808346
[TBL] [Abstract][Full Text] [Related]
9. [Effect of erythropoietin combined with granulocyte-colony stimulating factor in the treatment of acute myocardial infarction in rats].
Fu ZH; Dong W; Gai LY; Wang F; Ding R; Chen YD
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jan; 31(1):17-22. PubMed ID: 21269949
[TBL] [Abstract][Full Text] [Related]
10. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury.
Fiordaliso F; Chimenti S; Staszewsky L; Bai A; Carlo E; Cuccovillo I; Doni M; Mengozzi M; Tonelli R; Ghezzi P; Coleman T; Brines M; Cerami A; Latini R
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2046-51. PubMed ID: 15671158
[TBL] [Abstract][Full Text] [Related]
11. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Parissis JT; Kourea K; Panou F; Farmakis D; Paraskevaidis I; Ikonomidis I; Filippatos G; Kremastinos DT
Am Heart J; 2008 Apr; 155(4):751.e1-7. PubMed ID: 18371487
[TBL] [Abstract][Full Text] [Related]
12. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure.
Li Y; Takemura G; Okada H; Miyata S; Maruyama R; Li L; Higuchi M; Minatoguchi S; Fujiwara T; Fujiwara H
Cardiovasc Res; 2006 Sep; 71(4):684-94. PubMed ID: 16828072
[TBL] [Abstract][Full Text] [Related]
13. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure.
Bahlmann FH; Song R; Boehm SM; Mengel M; von Wasielewski R; Lindschau C; Kirsch T; de Groot K; Laudeley R; Niemczyk E; Güler F; Menne J; Haller H; Fliser D
Circulation; 2004 Aug; 110(8):1006-12. PubMed ID: 15302785
[TBL] [Abstract][Full Text] [Related]
14. [Alterations in aortic vasomotor function in rats with chronic heart failure and its mechanism].
Zhang HL; Zhao M; He X; Jiang HK; Yu XJ; Ma X; Zang WJ
Sheng Li Xue Bao; 2010 Aug; 62(4):317-24. PubMed ID: 20717632
[TBL] [Abstract][Full Text] [Related]
15. Chronic erythropoietin treatment decreases post-infarct myocardial damage in rats without venous thrombogenic effect.
Prunier F; Pottier P; Clairand R; Mercier A; Hajjar RJ; Planchon B; Furber A
Cardiology; 2009; 112(2):129-34. PubMed ID: 18596374
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
Sanganalmath SK; Barta J; Takeda N; Kumamoto H; Dhalla NS
Can J Physiol Pharmacol; 2008 Apr; 86(4):180-9. PubMed ID: 18418427
[TBL] [Abstract][Full Text] [Related]
17. [Erythropoietin enhances the therapy potency of autologous bone marrow stromal cells in a rat heart infarction model via phosphatidylinositol-3-kinase/Akt pathway].
Zhang DG; Zhang FM; Zhang YQ; Zhou F; Gao X; Li CF; Cao KJ
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):912-6. PubMed ID: 17217721
[TBL] [Abstract][Full Text] [Related]
18. [The myocardium protective effects of erythropoietin (EPO) in a rat model of asphyxia-induced cardiac arrest/cardiopulmonary resuscitation (CPR)].
Jiang HL; Zhu YC; Chen XH; Lin PY; Wang HJ
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Oct; 23(10):608-12. PubMed ID: 22005562
[TBL] [Abstract][Full Text] [Related]
19. Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury.
Piuhola J; Kerkelä R; Keenan JI; Hampton MB; Richards AM; Pemberton CJ
Clin Sci (Lond); 2008 Feb; 114(4):293-304. PubMed ID: 17919123
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties.
Moon C; Krawczyk M; Paik D; Coleman T; Brines M; Juhaszova M; Sollott SJ; Lakatta EG; Talan MI
J Pharmacol Exp Ther; 2006 Mar; 316(3):999-1005. PubMed ID: 16306273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
